Aga Khan Leads the Region in Advancing Prostrate Cancer Treatment
Kenya · ·
Aga Khan University Hospital Section Head, Nuclear Radiology, Dr Samuel Nguku and Chair, Department of Radiology, Dr Khalid Makhdomi analyse a scan image for one of the patients who received the Lutetium-177 PSMA therapy, an advanced nuclear medicine treatment for patients with advanced prostate cancer.
There is new hope for prostate cancer patients as Aga Khan University Hospital pioneers advanced nuclear medicine therapy in Kenya. Aga Khan Chief Executive Officer, Rashid Khalani announced the introduction of Lutetium-177 PSMA therapy at their facility, highlighting a significant advancement in prostate cancer treatment in…
There is new hope for prostate cancer patients as Aga Khan University Hospital pioneers advanced nuclear medicine therapy in Kenya. Aga Khan Chief Executive Officer, Rashid Khalani announced the introduction of Lutetium-177 PSMA therapy at their facility, highlighting a significant advancement in prostate cancer treatment in Kenya. This initiative aims to reduce the necessity for patients to seek specialised medical care abroad, reducing the financial and emotional burden of international travel. “As a hospital, we are committed to bringing the most advanced treatments to Kenya so that we can significantly improve patient outcomes,” he emphasised.
